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Abstract
Background
The vasoactive intestinal peptide (VIP) receptors VPAC1 and VPAC2 mediate anti-inflam-
matory and immunoregulatory responses in rheumatoid arthritis (RA). Data on the expres-
sion of these receptors could complement clinical assessment in the management of RA.
Our goal was to investigate the correlation between expression of both receptors and the
28-Joint Disease Activity Score (DAS28) in peripheral blood mononuclear cells (PBMCs)
from patients with early arthritis (EA). We also measured expression of IL-6 to evaluate the
association between VIP receptors and systemic inflammation.
Methods
We analyzed 250 blood samples collected at any of the 5 scheduled follow-up visits from
125 patients enrolled in the Princesa Early Arthritis Register Longitudinal study. Samples
from 22 healthy donors were also analyzed. Sociodemographic, clinical, and therapeutic
data were systematically recorded. mRNA expression levels were determined using real-
time PCR. Then, longitudinal multivariate analyses were performed.
Results
PBMCs from EA patients showed significantly higher expression of VPAC2 receptors at
baseline compared to healthy donors (p<0.001). With time, however, VPAC2 expression
tended to be significantly lower while VPAC1 receptor expression increased in correlation
with a reduction in DAS28 index. Our results reveal that more severe inflammation, based
on high levels of IL-6, is associated with lower expression of VPAC1 (p<0.001) and con-
versely with increased expression of VPAC2 (p<0.001). A major finding of this study is that
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expression of VPAC1 is lower in patients with increased disease activity (p = 0.001), thus
making it possible to differentiate between patients with various degrees of clinical disease
activity.
Conclusion
Patients with more severe inflammation and higher disease activity show lower levels of
VPAC1 expression, which is associated with patient-reported impairment. Therefore,
VPAC1 is a biological marker in EA.
Introduction
Rheumatoid arthritis (RA) is a common autoimmune disease with a heterogeneous clinical
course and various pathogenic mechanisms leading to chronic synovitis and joint destruction.
Macrophages, lymphocytes and other effector cell types, along with a wide range of inflamma-
tory and growth factors, are involved in a complex network whose balance is shifted both sys-
temically and locally towards a proinflammatory state [1]. The main features of RA are joint
pain, swelling and stiffness, as well as increased levels of acute phase reactants. These features
correlate with joint damage and are commonly used to assess the activity of RA [2]. Frequent
measurement of disease activity is recommended by the American College of Rheumatology/
European League Against Rheumatism [3], the European League Against Rheumatism [4] and
the treat-to-target international task force [5], with a clear goal, namely, reducing, if not elimi-
nating, inflammation to facilitate remission in the fastest possible way [6]. For this reason,
many investigators aim to identify biological markers reflecting underlying pathophysiological
processes associated with the clinical activity of RA.
Vasoactive intestinal peptide (VIP) is a broadly distributed peptide produced by neural,
endocrine and immune cells. Multiple studies have shown its involvement in the maintenance
of homeostasis and health [7–9].
The potent immunomodulatory functions of VIP have been demonstrated both in vivo, in a
murine model of collagen-induced arthritis [10], and ex vivo, in cultured fibroblast-like syno-
viocytes and in peripheral blood lymphocytes of patients with rheumatoid arthritis [10, 11].
We recently reported promising findings about the role of endogenous VIP in early arthritis
(EA), showing that patients with low baseline VIP levels have worse disease outcome [12]. The
protective effect of VIP has been attributed to 3 key features: anti-inflammatory properties, reg-
ulation of CD4+ T-cell subpopulations and modulation of mediators involved in the destruc-
tion of bone and cartilage [10, 13–15].
VIP triggers its biological responses by interacting with 2 subtypes of the class B family of G
protein–coupled receptors, VPAC1 and VPAC2 [16]. VPAC1 is constitutively expressed in
monocytes/macrophages and lymphocytes [17]. VPAC2 has also been described in lympho-
cytes and macrophages as an inducible receptor after immune stimulation [17]. Dynamic regu-
lation of VPAC1 and VPAC2 receptors has been reported in both physiological and
pathological processes [18]. Thus, altered expression of VPAC2 receptor has been reported in
monocytes isolated from patients with Sjögren’s syndrome [19] and in activated CD4+ T cells
from patients with multiple sclerosis [20]. Furthermore, decreased VPAC1 surface expression
in peripheral blood mononuclear cells (PBMCs) [21] and increased VPAC2 expression in
fibroblast-like synoviocytes [22] have been demonstrated in RA. Although these findings reveal
abnormal expression of VIP receptors in autoimmune diseases, their association with clinical
course has not been investigated.
VPAC1 and VPAC2 Expression in Early Arthritis
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Given the ability of VIP to regulate the intensity of the inflammatory process and the
immune response, together with the particular expression pattern of VIP receptors in RA, we
hypothesized that expression of VPAC1 and VPAC2 might be associated with disease activity
and would thus reflect the patient’s clinical status.
Therefore, our goal was to investigate the association between the expression of VIP recep-
tors during the follow-up of patients with EA and the degree of systemic inflammatory activa-
tion. To do so, we evaluated IL-6 expression levels and assessed the well-recognized disease
activity score based on the assessment of 28 joints (DAS28) [23].
Materials and Methods
Ethics statement
This study was undertaken in compliance with the Declaration of Helsinki. The protocol for
the Princesa Early Arthritis Register Longitudinal (PEARL) study was reviewed and approved
by the Ethics Committee for Clinical Research at the Instituto de Investigación Sanitaria La
Princesa. All patients were informed about the study and signed an informed consent form
before inclusion in the register.
Patients and Controls
The PEARL study includes patients with more than 1 swollen joint for at least 4 weeks and
symptoms for less than a year. The register protocol includes collection of socio-demographic,
clinical and therapeutic data, as well as samples at each of the 5 scheduled visits (baseline, 6, 12,
24 and 60 months). A more detailed description of the protocol has been published elsewhere
[12].
For the present study, we used 250 blood samples collected during the follow-up of 125
patients enrolled in the PEARL study. Among these, 79 fulfilled the 2010 American College of
Rheumatology/European League Against Rheumatism criteria for Rheumatoid Arthritis [24]
and 46 patients were diagnosed with chronic undifferentiated arthritis. None of these 46
patients fulfilled the criteria for other inflammatory disorders (infectious arthritis, microcrys-
talline arthritis, connective tissue diseases, spondyloarthritis or psoriatic arthritis). Regarding
received treatment, there were 85 visits in which patients were not under disease modifying
antirheumatic drugs (DMARD) treatment, mostly baseline visits and few follow-up visits from
patients with mild disease. In 128 visits patients were under DMARD monotherapy: 65% on
methotrexate (MTX), 20% on leflunomide (LEF), 10% on antimalarials (AM) and other
DMARDs 5%. Finally, in 37 visits patients received combined DMARD treatment with a very
heterogeneous profile including MTX+LEF (40%), MTX+AM (18%) and TNF-blockers+-
different DMARDS (26%), other combinations included MTX+SSZ, LEF+SSZ, LEF+AM and
so on.
Healthy donors (n = 22) were recruited from Hospital Universitario de La Princesa. This
group included 9 women and 13 men, whose median and interquartile range (IQR) age was 38
(30–49).
Semiquantitative real-time reverse transcription-polymerase chain
reaction (RT-PCR) assay
PBMCs from EA patients and blood samples from healthy donors were isolated using Ficoll
density gradient centrifugation (Histopaque-1077™, Sigma-Aldrich). The expression of
VPAC1, VPAC2 and IL-6 in PBMCs was analyzed by RT-PCR. Total RNA was obtained from
PBMCs using TRI Reagent™ (Sigma-Aldrich), and 2 μg was reverse transcribed using the High
VPAC1 and VPAC2 Expression in Early Arthritis
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Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Complementary DNA (25
ng/well) was amplified by semiquantitative real-time PCR performed with TaqMan Gene
Expression Master Mix (Applied Biosystems) using manufacturer-predesigned primers
(Applied Biosystems. VPAC1: Hs00270351_m1; VPAC2: Hs00173643_m1; IL-6:
Hs00985639_m1). Data were normalized for relative quantification and expressed in reference
to the β-actin housekeeping gene using the 2-ΔΔCt formula, as previously described [22].
Statistical analysis
Descriptive analysis: quantitative variables were represented as the mean ± standard deviation
(SD). Variables with equal variances were analyzed using the t test or ANOVA (analysis of var-
iance). Comparisons between the groups were made a posteriori using multiple comparison
tests. The MannWhitney or Kruskal-Wallis test was used for variables with unequal variances,
and intergroup comparison was done by the multiple comparison test—non-parametric poste-
riori test. Homoscedasticity was assessed using Levene’s test and an ANOVA or t- test (n>30).
Normality was not assessed. The trend test was used to study the evolution of VPAC1, VPAC2,
the VPAC1:VPAC2 ratio and IL-6 during follow-up.
The association between expression of VPAC receptors and disease activity based on
DAS28 was analyzed using univariate and multivariate GEE (generalized estimating equations
method) with gaussian family and identity link function. Variability in the statistics derived
from visit observations was analyzed using exchangeable correlation structures. The multivari-
ate model included variables with p<0.20 in the univariate analysis. Considering that the raw
data for gene expression contained left-shifted values, we decided to censor values above the
95th percentile. An appropriate transformation was applied to perform the analysis in cases of
non-normal distribution. The association between quantitative variables was analyzed using
Spearman’s correlation test. p values0.05 were considered statistically significant. The statis-
tical analyses were performed using Stata 13 for Windows (StataCorp LP, College Station,
Texas, USA).
Results
Patient characteristics. Expression of VPAC1 and VPAC2 in PBMCs
during follow-up
A total of 125 patients with RA (n = 79) or chronic undifferentiated arthritis (n = 46) were
included in the study. Patients who fulfilled the 1987 criteria for RA [25] had more severe dis-
ease at baseline and a higher positivity of 2 validated biomarkers of diagnosis and severity
(rheumatoid factor [RF] and anti-citrullinated peptide antibodies [ACPA]) than patients with
undifferentiated arthritis (Table 1).
During follow-up protocol, disease activity was evaluated. As shown in Fig 1, significantly
lower scores in disease activity were observed over the course of the disease as a consequence of
adjusting treatment with glucocorticoids or DMARDs (see Materials and Methods).
We first analyzed the gene expression of both subtypes of VIP receptors (VPAC1 and
VPAC2) in PBMCs isolated at baseline visit from EA patients and from controls. Slightly lower
expression of VPAC1 was found in EA patients, although the difference was not statistically
significant (1.2 ± 0.1 vs 1.6 ± 0.2, respectively; p = 0.1, Mann-Whitney test). In contrast,
PBMCs from patients exhibited significantly higher mRNA levels of VPAC2 than PBMCs
from healthy donors (1.7 ± 0.3 vs 0.8 ± 0.1, respectively; p<0.001, Mann-Whitney test).
Next, we studied expression of VPAC1 and VPAC2 during follow-up. As Fig 2A shows,
expression of VPAC1 increased significantly (p-trend = 0.029), reaching the highest values
VPAC1 and VPAC2 Expression in Early Arthritis
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after 2 years of follow-up. Conversely, VPAC2 expression decreased (p-trend = 0.024, Fig 2B).
(Ct values of real-time PCR assay are shown in S1 Table). In order to assess the relationship
between both receptors during follow-up, we evaluated the VPAC1:VPAC2 ratio in PBMCs for
each patient. The ratio had increased during follow-up (from 1.3 ± 0.3 at baseline to 7.7 ± 1.6 at
5 years), suggesting dynamic regulation of both receptors (Fig 2C). After adjustment for visits,
an inverse correlation between both receptors was confirmed (r = –0.60, p<0.001); therefore,
increased expression of VPAC1 is associated with decreased expression of VPAC2 (Fig 2D).
As a consequence of limitations in systematic RNA extraction at the beginning of the regis-
ter, many patients lacked data for all 5 visits. We therefore performed a new analysis consider-
ing only those patients with samples from 3 or 4 visits including baseline and similar results
were obtained (S1 Fig).
Correlation between VPAC receptors and IL-6 expression in EA patients
IL-6 is considered a marker of systemic inflammation in RA [26]. Therefore, we decided to
investigate whether there was an association between IL-6 levels and expression of VIP recep-
tors. First, we evaluated the evolution of IL-6 expression in our EA cohort. As expected, IL-6
levels were highest at the beginning of follow-up and decreased over time (Fig 3A). (Ct values
of real-time PCR assay was shown in S1 Table). We then performed a correlation analysis
adjusted for the visits. As shown in Fig 3B, expression of VPAC1 was significantly lower at vis-
its where a higher level of IL-6 was detected. Conversely, a significant and positive correlation
was detected between this inflammatory marker and VPAC2 expression (Fig 3C).
Association between higher DAS28 levels and reduced VPAC1 receptor
expression. Evaluation of subgroups by DAS28 level
Given that the most obvious change during follow-up is that patients improved once they are
treated [27], we next analyzed the expression of the receptors taking into account the level of
disease activity (remission, low, moderate or high) assessed through DAS28. We performed a
Table 1. Baseline characteristics of patients with early arthritis.
Rheumatoid Arthritis (n = 79) Undifferentiated Arthritis (n = 46) Total (n = 125) p-value
Age* (years) 53 [45–70] 52 [40–68] 52 [44–68] NS
Gender** (female) 82 76 80 NS
Ethnicity** (caucasian) 64 (81%) 41 (89.1%) 105 (84%) NS
Disease duration* (months) 5.4 [3.1–8.1] 4.6 [2.2–7] 5.1 [2.8–7.7] 0.1
GDA Pat* 50 [30–64] 42 [23–50] 47 [27–58] 0.003
GDA Phy* 50 [32–65] 26 [10–47] 41 [23–55] <0.001
HAQ* 1.125 [0.750–1.750] 0.875 [0.375–1.125] 1 [0.625–1.500] 0.002
CRP (mg/dl) * 0.9 [0.3–2.3] 0.4 [0.2–0.9] 0.7 [0.2–1.7] 0.014
ESR (mm/h)* 32 [20–55] 21 [13–37] 27 [16–50] 0.036
DAS28 (0–10)* 5.1 [3.7–6.1] 3.6 [2.6–4.8] 4.5 [3.4–5.6] <0.001
RF+** 72 11 50 <0.001
ACPA+** 66 11 46 <0.001
Data are shown as the *median [interquartile range] or, **n (%). GDA: Global Disease Assessment; Pat: patient; Phy: physician; HAQ: health
assessment questionnaire; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DAS28: 28-joint disease activity score; RF: rheumatoid factor;
ACPA: anti-citrullinated peptide antibodies. Statistical signiﬁcance was established using the Pearson chi-square test for a p value<0.05. NS: non-
signiﬁcant.
doi:10.1371/journal.pone.0149141.t001
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multivariate analysis to ensure a more accurate appraisal. Our data showed that higher levels of
DAS28 were associated with lower gene expression of VPAC1 (Table 2). Similar results were
also observed at protein level (S2 Fig). In addition, VPAC1 expression tended to be signifi-
cantly higher in patients treated with combinations of disease-modifying antirheumatic drugs
and in Latin American patients. We did not detect any association between VPAC2 expression
and the variables studied (Table 3).
We analyzed VPAC1 expression in EA patients clustered into 3 sub-groups by their DAS28
levels (remission-low, moderate and high disease activity). As Fig 4 shows, patients with mod-
erate or high activity expressed significantly lower levels of VPAC1. By contrast, patients in
remission displayed higher VPAC1 expression.
Correlation between VPAC1 expression and global disease assessed
by patients and physicians
Patient perspectives have become an increasingly relevant component of RA outcome mea-
surement, and the physician’s global assessment is the only way to quantify the patient’s opin-
ion of disease course [28]. Therefore, patient and physician global scores were analyzed. A
Fig 1. Progress of disease activity estimated by DAS28 at follow-up visits. Data are presented as the interquartile range (p75 upper edge of the box, p25
lower edge, p50 midline), p90 (line above the box), and p10 (line below the box). Dots represent outliers. Statistical significance was established using the
Kruskal-Wallis test.
doi:10.1371/journal.pone.0149141.g001
VPAC1 and VPAC2 Expression in Early Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0149141 February 16, 2016 6 / 15
negative correlation was observed between VPAC1 expression and global disease activity both
by the patient and by the physician (Table 4). As VPAC1 seems to be a marker of disease activ-
ity in EA, we decided to compare it with 2 acute phase reactants that are commonly used to
monitor disease activity in RA, namely, the erythrocyte sedimentation rate (ESR) and C-reac-
tive protein (CRP). Both of them correlate well with IL-6 levels, however it has been described
that they are subject to a gender bias [29]. Consequently, a more useful biological marker for
disease activity is needed.
Since ESR is included in the DAS28, we used global disease assessment by the physician and
the patient as an independent gold standard to compare VPAC1 expression with ESR and CRP
Fig 2. Evolution of gene expression levels of VPAC1 and VPAC2 in PBMCs from EA patients. (A) and (B) Variation in gene expression levels of
VPAC1 (panel A) and VPAC2 (panel B) receptors at follow-up visits. (C) Evolution of the ratio of gene expression of both receptors during the follow-up. (D)
Correlation between gene expression levels of VPAC1 and VPAC2 receptors. Statistical significance was established using the Trend test and non-
parametric posteriori test (Dunnett) for intergroup comparison, in panels A, B and C. In panel D, the significance level was obtained by means of a
generalized linear model nested by patient and visit. In panel D dots represent average data from patients clustered by visits from 1 to 5. Data of A, B and C
panels are represented as the interquartile range (p75 upper edge of the box, p25 lower edge, p50 midline), p90 (line above the box), and p10 (line below the
box) of the expression of VPACs receptors. Mathematical transformation for VPAC expression: raised to 0.3. Dots represent outliers.
doi:10.1371/journal.pone.0149141.g002
VPAC1 and VPAC2 Expression in Early Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0149141 February 16, 2016 7 / 15
values. As shown in Table 4, although serum CRP correlated slightly better with both assess-
ments than VPAC1 expression, VPAC1 was more useful than ESR in estimating global disease
activity (Table 4).
Discussion
Knowledge of deregulated key factors in the pathophysiological processes of RA can comple-
ment clinical assessment [30]. Many studies have emphasized the importance of VIP and their
receptors in modulating inflammatory and immune responses in RA [10, 11, 13, 31]. In recent
years, VIP levels have emerged as a suitable prognostic biomarker in EA, since patients who
are unable to up-regulate VIP have a poorer clinical course [12]. In the present study, we pro-
vide new evidence of the functional relevance of this peptide through the association between
the level of expression of VPAC1 in PBMCs and the patient’s clinical status.
VPAC1 is expressed at slightly lower levels in the PBMCs of patients with EA than in those
of healthy donors, although the difference is not significant. VPAC2, however, is expressed at
higher levels in patients with EA. Using flow cytometry, Delgado et al [21] showed decreased
Fig 3. Correlation between gene expression levels of VPACs receptors and IL-6 in PBMCs from EA patients. (A) Evolution of IL-6 expression in the
EA cohort during the follow-up. Data are represented as the interquartile range (p75 upper edge of the box, p25 lower edge, p50 midline), p90 (line above the
box), and p10 (line below the box) of the expression of IL-6. Dots represent outliers. (B) and (C) Correlation between gene expression of VPAC1 and IL-6
(panel B) and between VPAC2 and IL-6 (panel C). Statistical significance was established using the Trend test and non-parametric posteriori test (Dunnett)
for intergroup comparison, in panel A. In panels B and C the significance level was obtained by means of a generalized linear model nested by patient and
visit. In panels B and C dots represent data from patients clustered by visits from 1 to 5.
doi:10.1371/journal.pone.0149141.g003
VPAC1 and VPAC2 Expression in Early Arthritis
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expression of VPAC1 in PBMCs from patients with RA, probably as a result of altered gene
regulation, although no data were reported for RNA expression [21]. The increased expression
of VPAC2 receptors shown here might reflect a compensating mechanism operating in vivo. In
fact, the present study is the first to demonstrate a converse change in the expression of
VPAC1 and VPAC2 in PBMCs during the course of EA.
Previous studies demonstrated polarization toward a Th1/Th17 response and exacerbated
experimental autoimmune encephalomyelitis in mice lacking the immune-inducible VPAC2
receptor [32, 33]. In addition, transgenic mice expressing VPAC2 display a shift in CD4 T-cell
polarization towards a Th2 phenotype [33, 34]. Our findings indicate that lower expression of
VPAC1 in PBMCs is correlated with an increase in VPAC2 expression that could be explained
as an attempt to counteract the imbalance of Th1/17 and Th2 in RA. Indeed, in Th17-polarized
cells from EA patients, expression of VPAC2 predominates over VPAC1 [35]. Moreover,
Table 2. Multivariate analysis of variables associated with VPAC1 expression during follow-up of patients with early arthritis.
β Coeff. 95% CI p-value
DAS28 -0.070 [-0.10–-0.300] 0.000
Corticosteroids -0.002 [-0.10–0.004] 0.483
DMARDs
None Ref.
Monotherapy 0.080 [-0.003–0.170] 0.059
Combined therapy 0.220 [0.090–0.340] 0.001
Origin
Spain Ref.
South America 0.140 [0.020–0.270] 0.025
Eastern Europe 0.290 [-0.270–0.850] 0.304
The longitudinal multivariate analysis was performed with data (mathematical transformation for VPAC1 expression: raised to 0.3) from 207 visits
corresponding to the 79 rheumatoid arthritis patients with all information available for 2 visits. β Coeff.: β coefﬁcient of the Wald test; CI: conﬁdence
interval; DAS28: 28-joint disease activity score; DMARD: disease-modifying antirheumatic drugs. The table shows all the variables reaching p<0.2 in the
bivariate analysis.
doi:10.1371/journal.pone.0149141.t002
Table 3. Multivariate analysis of variables associated with VPAC2 expression during follow-up of patients with early arthritis.
β Coeff. 95% CI p-value
DAS28 -0.01 [-0.04–0.02] 0.540
Corticosteroids -0.0002 [-0.01–0.01] 0.940
DMARDs
None Ref.
Monotherapy 0.003 [-0.08–0.08] 0.946
Combined therapy 0.05 [-0.06–0.17] 0.367
Origin
Spain Ref.
South America 0.001 [-0.11–0.12] 0.992
Eastern Europe 0.45 [-0.07–0.98] 0.090
The longitudinal multivariate analysis was performed with data from 210 visits corresponding to the 79 rheumatoid arthritis patients with all information
available for 2 visits. β Coeff.: β coefﬁcient of the Wald test; CI: conﬁdence interval; DAS28: 28-joint disease activity score; DMARD: disease-modifying
antirheumatic drugs. The table shows all the variables reaching p<0.2 in the bivariate analysis.
doi:10.1371/journal.pone.0149141.t003
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VPAC2 is able to mediate anti-inflammatory effects when expression of VPAC1 is reduced
[22]. Future studies will examine the functional relevance of the higher expression of VPAC2
receptors in the PBMCs of patients with EA and whether this constitutes a compensatory
mechanism or is simply an event brought about by damage associated with chronic
inflammation.
The sustained high expression of IL-6 is a key inducer of systemic inflammation in RA and
is associated with disease activity [36]. In our cohort, expression of IL-6 decreased during fol-
low-up, probably as a result of the effectiveness of disease-modifying antirheumatic drugs. Our
Fig 4. Correlation between VPAC1 gene expression levels and disease activity.Data are represented as the interquartile range (p75 upper edge of the
box, p25 lower edge, p50 midline), p90 (line above the box) and p10 (line below the box). Mathematical transformation for VPAC1 expression: raised to 0.3.
Dots represent outliers. Statistical significance was established using the Kruskal-Wallis test.
doi:10.1371/journal.pone.0149141.g004
Table 4. Correlation between VPAC1 expression and global disease assessment.
ESR CRP VPAC1
β Coeff. p-value β Coeff. p-value β Coeff. p-value
GDAPa 0.182 0<0.001 0.331 <0.001 -0.219 0.002
GDAPh 0.268 <0.001 0.468 <0.001 -0.305 <0.001
Spearman’s correlation test performed with quantitative variables GDAPa: global disease activity assessed by patient; GDAPh: global disease activity
assessed by physician. β Coeff.: β coefﬁcient of Spearman’s test. Statistical signiﬁcance was set at p<0.05.
doi:10.1371/journal.pone.0149141.t004
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results reveal that more severe inflammation, seen as high levels of IL-6, is associated with
lower expression of VPAC1 and, conversely, with increased expression of VPAC2. Interest-
ingly, a major finding of the present study is that patients with a higher degree of disease activ-
ity show lower expression of VPAC1. In addition, expression of VPAC1 makes it possible to
differentiate between patients with various degrees of clinical disease activity. VIP signaling
through VPAC1 considerably inhibits the G1/S transition of the cell cycle in human T cells,
and the expression of this receptor is down-regulated in activated T-cells [17, 18]. Thus,
VPAC1 signaling appears to block the signal that causes its down-regulation and might be the
reason why low expression of VPAC1 has been observed in cell lines and blasts from patients
with leukemia [18]. Given that proliferative response and hyperactivity of CD4+ T cells are
characteristics that contribute to the pathogenesis of RA, expression of VPAC1 could serve as
an indicator of deregulated activation of the immune system. To date, we do not know whether
changes in VPAC1 expression are a cause or a consequence of the disease, although our results
suggest a protective role for this receptor in EA. The multiplicity and diversity of activities
exerted when VPAC1 binds to VIP consistently supports this possibility. In fact, both animal
and human models of RA have demonstrated that selective activation of VPAC1 is more effec-
tive for controlling the immune response than VPAC2 agonists [37]. Accordingly, treatment
with a VPAC1 agonist, but not with a VPAC2 agonist, reduced the frequency of arthritis, ame-
liorated symptoms, and prevented joint damage in an experimental model of arthritis [7]. In
addition, treatment with a VPAC1 agonist decreased the inflammatory response during pro-
gression of collagen-induced arthritis by down-regulating the production of various inflamma-
tory mediators and reduced the presence of autoreactive Th1 cells in the joints [21].
The fact that patients treated with monotherapy or combinated therapy exhibit higher levels
of VPAC1 expression but not VPAC2 suggests that VPAC1 receptor regulation is probably
sensitive to disease-modifying antirheumatic drugs, as shown for several cytokines and their
receptors [38, 39]. Antirheumatic agents could act indirectly by modifying the profile of
immune cell types bearing VPAC1/2 receptors within the population of PBMCs. In fact, com-
bined therapy increased the number of lymphocytes and monocytes (S3 Fig) which was associ-
ated with increased expression of VPAC1 but it was not correlated with VPAC2 expression (S2
Table). However, the lymphocytes:monocytes ratio was not affected by prescribed treatments
and no association was observed with VPACs receptors expression (S3 Fig). Moreover, anti-
inflammatory agents could change the relative proportions of specific lymphocyte subpopula-
tions expressing VPACs receptors. In this sense, it has been described that Th17 polarization
induces a higher expression of both receptors in EA patients mainly of the VPAC2 receptor
[35]. Thus, a shift in the relative levels of the different T cell subpopulations during treatment
could eventually result in changes in the VPAC1 expression. Finally, DMARD might act
directly by regulating the expression of VPAC1 receptor on lymphocytes and monocytes.
Therefore, VPAC1 could serve as an indicator for clinical observation of disease activity and
also as a therapeutic target in RA.
Finally, our results reveal that expression of VPAC1 correlates with global disease activity as
estimated by patients and physicians in much the same way as currently used biomarkers of
disease activity. This observation is interesting, because the patient’s perception has been
repeatedly shown to have crucial predictive value [40]. Although patient perspectives per se are
subjective, they will likely serve as a benchmark to improve not only traditional objective mea-
sures of disease activity, but also patient satisfaction [41].
The mechanisms involved in the regulation of the expression of VPAC1 in immune cells
from patients with EA remain unknown. Although predisposition to RA has been associated
with a haplotype in the VPAC1 3´-UTR [21], no evidence of an association with clinical vari-
ables has emerged. Ongoing and future studies investigating the molecular mechanisms
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regulating VPAC1 are essential for better understanding of its role in inflammatory disease
and autoimmunity.
In conclusion, patients with more severe inflammation and high disease activity show lower
levels of VPAC1 expression associated with patient-reported impairment. Although the mech-
anisms of VPAC1 regulation have yet to be elucidated, emerging evidence supports the clinical
relevance of VPAC1 expression in RA.
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S1 Appendix. Materials and Methods of Western blot analysis of VPAC1 receptor.
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S1 Fig. Evolution of gene expression levels of VPAC1 and VPAC2 in PBMCs from EA
patients with 3 or 4 visits. (A) and (B) Variation in gene expression levels of VPAC1 (panel
A) and VPAC2 (panel B) receptors. Statistical significance was established using the Trend test
and non-parametric posteriori test (Dunnett) for intergroup comparison.
(TIF)
S2 Fig. VPAC1 protein expression studied by Western Blot analysis of PBMCs lysates from
patients with RA with differential DAS28 levels. A) Samples from a couple of patients in visit
1 with low and high DAS28 level, respectively. A representative example of two analyses with
similar results is shown. B) Samples from one patient in two consecutive visits during the fol-
low-up, after and before receiving treatment. In both panels protein bands were densitometri-
cally analyzed and normalized against beta-actin intensity. Pictures are a representative
example. ARC: Arthritis Register Code for each patient. V: Visit number.The protocol of
PEARL study does not include storing samples for intracellular proteins analysis. Therefore, it
was not possible to perform the protein analysis during the course of the disease in parallel to
gene expression studies and it was only conducted on a few patient samples.
(TIF)
S3 Fig. Variations in the relative proportions of different cell populations of PBMCs
related to the administration of combined therapy. A) Proportion of lymphocytes in patients
with no treatment or with combined therapy. B) Proportion of monocytes in patients with no
treatment or with combined therapy. C) Representation of the ratio lymphocytes/monocytes in
patients with no treatment or with combined therapy. Statistical significance was establish by
means of a Kruskal-Wallis test: p<0,05.
(TIF)
S1 Table. Ct Values of real-time PCR assay. Data are shown as the mean ± standard devia-
tion.
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S2 Table. Association between VPAC1 and VPAC2 expression and cell population propor-
tions in patients with combined therapy. The association was studied by means of a univari-
ate GEE (generalized estimating equations method).
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